{"id":"androgen-blockade-radiation-therapy","safety":{"commonSideEffects":[{"rate":"40-70","effect":"Erectile dysfunction"},{"rate":"50-80","effect":"Hot flashes"},{"rate":"30-50","effect":"Fatigue"},{"rate":"20-40","effect":"Bowel toxicity (diarrhea, proctitis)"},{"rate":"20-35","effect":"Urinary toxicity (dysuria, frequency)"},{"rate":"10-20","effect":"Gynecomastia"},{"rate":"50-80","effect":"Decreased libido"}]},"_chembl":{"chemblId":"CHEMBL1200527","moleculeType":"Small molecule","molecularWeight":"1243.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Androgen deprivation therapy (ADT) inhibits the androgen receptor signaling pathway that drives prostate cancer proliferation, rendering cancer cells more radiosensitive. Concurrent radiation therapy exploits this sensitized state to deliver localized high-dose ionizing radiation that causes DNA damage and cell death. The combination approach aims to improve local control and overall survival in prostate cancer patients.","oneSentence":"Androgen blockade suppresses testosterone-driven prostate cancer cell growth, while radiation therapy delivers targeted cytotoxic damage to tumor cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:38.058Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced prostate cancer"},{"name":"High-risk prostate cancer"}]},"trialDetails":[{"nctId":"NCT07182279","phase":"PHASE1, PHASE2","title":"Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2025-08-01","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":29},{"nctId":"NCT06855277","phase":"PHASE3","title":"Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-07-01","conditions":"Prostate Cancer","enrollment":940},{"nctId":"NCT07393867","phase":"PHASE2","title":"Androgen-responsive POSLUMA-guided Intra-prostatic Boost","status":"NOT_YET_RECRUITING","sponsor":"Martin T. King, MD, PhD","startDate":"2026-03","conditions":"Intermediate Risk Prostate Cancer, High Risk Prostate Cancer, Prostate Cancer","enrollment":23},{"nctId":"NCT03543189","phase":"PHASE1, PHASE2","title":"Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-10-03","conditions":"Prostate Cancer, Prostate Disease","enrollment":44},{"nctId":"NCT04025372","phase":"PHASE2","title":"INTREPId (INTermediate Risk Erection PreservatIon Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2020-06-01","conditions":"Prostate Cancer","enrollment":234},{"nctId":"NCT00223145","phase":"PHASE3","title":"Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abdenour Nabid","startDate":"2000-12","conditions":"Prostate Cancer","enrollment":600},{"nctId":"NCT00223171","phase":"PHASE3","title":"Duration of Androgen Blockade Combined With Pelvic Irradiation in Prostate Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Université de Sherbrooke","startDate":"2000-10","conditions":"Prostate Cancer","enrollment":630},{"nctId":"NCT03777982","phase":"PHASE3","title":"Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-04-20","conditions":"Prostate Cancer","enrollment":12},{"nctId":"NCT03043807","phase":"PHASE2","title":"A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-02-22","conditions":"Prostate Cancer","enrollment":26},{"nctId":"NCT02064036","phase":"PHASE1","title":"Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2013-06-06","conditions":"Adenocarcinoma of the Prostate","enrollment":17},{"nctId":"NCT02716974","phase":"PHASE2","title":"A Study of Definitive Therapy to Treat Prostate Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-06","conditions":"Prostate Cancer","enrollment":26},{"nctId":"NCT03541928","phase":"PHASE2","title":"Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery","status":"UNKNOWN","sponsor":"The Methodist Hospital Research Institute","startDate":"2018-08-02","conditions":"High-risk Prostate Cancer, Prostate Cancer","enrollment":60},{"nctId":"NCT00002633","phase":"PHASE3","title":"Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"1995-02-08","conditions":"Prostate Cancer","enrollment":361},{"nctId":"NCT00924807","phase":"PHASE1, PHASE2","title":"Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer","status":"TERMINATED","sponsor":"Beth Israel Medical Center","startDate":"2008-09","conditions":"Prostate Cancer","enrollment":4},{"nctId":"NCT02382094","phase":"PHASE3","title":"Clinical Trial to Study Quality of Life in Prostate Cancer Patients by Randomizing Anti-androgen Versus Total Androgen Blockage Prior to Curative Intended Radiation Therapy","status":"COMPLETED","sponsor":"Karolinska University Hospital","startDate":"2005-06","conditions":"Prostate Cancer","enrollment":110},{"nctId":"NCT01839994","phase":"PHASE3","title":"Conformal Radiotherapy (CRT) Alone Versus CRT Combined With HDR BT or Stereotactic Body Radiotherapy for Prostate Cancer","status":"UNKNOWN","sponsor":"Maria Sklodowska-Curie National Research Institute of Oncology","startDate":"2013-06","conditions":"Prostate Cancer","enrollment":350},{"nctId":"NCT00003026","phase":"PHASE3","title":"Hormone Therapy in Treating Patients With Advanced Prostate Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1997-04","conditions":"Prostate Cancer","enrollment":966}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":104,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Androgen blockade + radiation therapy","genericName":"Androgen blockade + radiation therapy","companyName":"Université de Sherbrooke","companyId":"universit-de-sherbrooke","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Androgen blockade suppresses testosterone-driven prostate cancer cell growth, while radiation therapy delivers targeted cytotoxic damage to tumor cells. Used for Locally advanced prostate cancer, High-risk prostate cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}